The worldwide market for products to treat stress urinary incontinence (SUI) is currently put at 10 billion Euros and is growing at an annual rate of 10 per cent. It is estimated that there are around 47 million women and 4 million men with SUI in the seven major markets – USA, Germany, Japan, UK, France, Italy and Spain – approximately a quarter of which is actively seeking treatment. Each year, some 500,000 new patients come forward for treatment.
The various treatment methods available range from medical products, surgical interventions as well as implants of medical devices and inserts. In the past 10 years, more than a million SUI patients have opted for the surgical implanting of a sub-urethral sling.
ICES13, the main product from Innovacell, is therefore addressing a large and quickly growing market. In the world's seven major markets for pharmacological products, there are around 3.3 million patients who could benefit from treatment with ICES13 – 1.4 million of whom live in countries belonging to the European Union.